Beijing Chieftain Control Technology Group Co 300430.SZ · CNY
Industrials · Shenzhen · 🇨🇳 China
3.69
-3.66%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Beijing Chieftain Control Technology Group Co
Its shares trade on Shenzhen under the ticker 300430.SZ. It has been listed since 19 March 2015. In the fiscal year to 31 December 2025, it reported revenue of CN¥470.4m and a net loss of CN¥879.4m. At that date it held total assets of CN¥3.16bn and shareholders' equity of CN¥1.34bn.
Beijing Chieftain Control Engineering Technology Co. Ltd. engages in the provision of pharmaceutical and biotechnology industrial automation control system. The company is headquartered in Beijing, Beijing. The company went IPO on 2015-03-19. The firm focuses on automation control applications in the production process of pharmaceutical and biotechnology products, and provides automation control system products and integrated solutions to large and medium sized pharmaceutical, biotechnology companies, based on independent research and development of core technologies and independent produced key equipment and components. Its main products include four series: Fermentation and Synthesis, Purification, Product Preparation, as well as Auxiliary Process.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Industrials
- Industry
- Machinery
- Listed since
- 19 Mar 2015
- Employees
- 1,665
- Website
- ctntech.com ↗
Leadership
Pay as last reported
- Mr. Kai LiangChairman of the Board, General Manager, since 2020
- Mr. Zhenhua LuChief Financial Officer, Deputy General Manager, Director
- Mr. Tianjun HuangDeputy General Manager, Director
- Mr. Wenyong ZhuDeputy General Manager, Director, since 2020
- Ms. Jinting ZhangSecretary of the Board
- Mr. Yi LiangDirector
- Mr. Yuanlong LuoDirector
- Ms. Yanli FanIndependent Director
- Mr. Fuqing WangIndependent Director
- Ms. Yun XuIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- 1665 employees support robust automation control system development in pharmaceuticals.
- Beijing headquarters provides strategic location for industrial automation technology growth.
- Four product series cover key pharmaceutical production processes effectively.
Weaknesses
- IPO in 2015 limits recent market expansion opportunities.
- Pharmaceutical automation focus restricts diversification into other sectors.
- Limited to large and medium pharmaceutical companies for client base.
Opportunities
- Growing biotechnology sector in China offers new market potential.
- Expansion into pharmaceutical automation control for emerging markets.
- Increased demand for automation in biotechnology production processes.
Threats
- Competition from established automation control firms in China.
- Regulatory changes in pharmaceutical manufacturing standards.
- Economic downturns affecting pharmaceutical industry investments.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.